Pharmacy Strategies to Limit Business Disruption from Suspicious Order Monitoring On-Demand Webinar Replay

Frier Levitt is proud to offer a complimentary webinar replay recapping DEA rules regarding upstream supply chain reporting obligations, evolving suspicious order reporting and investigative requirements, and techniques designed to limit the degree of interruptions to your business as a result. 
 
The Drug Enforcement Administration, itself under fire for failing to effectively curb the Nation’s opioid epidemic, has increased pressure on industry, and wholesalers in particular, to limit the distribution of controlled substances. Pending DEA rules further seek to involve distributors in the investigation and reporting of their pharmacy clients by requiring “due diligence” in the filling of orders for controlled substances. The lack of clear uniform standards regarding the reporting of suspicious orders and due diligence investigations means that standards and criteria will be inconsistent from one wholesaler to the next, thereby increasing pharmacy burden, lack of transparency and business disruption. Pharmacies need to develop strategies to mitigate these adverse consequences. 
 
Our first presenter, Anthony Mahajan, Esq., previously served as Chief Counsel to McKesson Corp., where he was responsible for providing legal advice to the business regarding compliance with suspicious order reporting requirements and McKesson’s 2017 settlement with the Department of Justice and DEA regarding controlled substances. He also formerly worked as an Assistant United States Attorney in the District of New Jersey, where he investigated and prosecuted numerous controlled substance offenses against manufacturers, distributors, pharmacies and health care professionals. Mr. Mahajan currently serves as Chair of Frier Levitt’s White Collar Defense & Government Investigations practice. 
 
Our second presenter, Steven L. Bennet, Esq., is a Partner in Frier Levitt’s healthcare litigation practice group and works on litigation matters for healthcare professionals. Steven represents clients in a diverse range of disputes including insurance and Pharmacy Benefits Manager (PBM) network termination, wrongful exclusion from networks, PBM audits, Board of Pharmacy actions, Board of Medical Examiners actions, other governmental investigations, and commercial disputes. Through these representative matters, Steven has developed a comprehensive knowledge of federal and state laws and regulations, including Anti-Kickback laws and fraud, waste and abuse regulations. Steven routinely advises clients on strategies and best practices to avoid litigation risk.
 
Access the on-demand webinar replay “Pharmacy Strategies to Limit Business Disruption from Suspicious Order Monitoring” by filling out the form below:

    Share: